{"id":"v920-high-dose-lot","safety":{"commonSideEffects":[{"rate":"60-80%","effect":"Injection site pain"},{"rate":"50-70%","effect":"Fatigue"},{"rate":"40-60%","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:34:21.456504","_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The vaccine works by introducing a non-infectious component of the Ebola virus to stimulate an immune response, which can protect against future infection with the live virus.","oneSentence":"V920 High-dose Lot is a vaccine designed to prevent Ebola virus disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:05.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Ebola virus disease in individuals at risk of infection"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT02503202","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-17","conditions":"Prevention of Ebola Infection","enrollment":1197}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2019 Aug 30","pmid":"31505665","title":"Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.","journal":"The Journal of infectious diseases"},{"date":"2017 Jun 15","pmid":"28549145","title":"Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.","journal":"The Journal of infectious diseases"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"V920 High-dose Lot","genericName":"V920 High-dose Lot","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"V920 High-dose Lot is a vaccine designed to prevent Ebola virus disease. Used for Prevention of Ebola virus disease in individuals at risk of infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}